BRAF and Langer mesomelic dysplasia: Some of the results are very encouraging, as OS rates of 11 months and longer have been reported [101,102,103], but most of these patients were treatment-naïve to BRAF inhibitor monotherapy and/or dual therapy with BRAF inhibitors and mitogen-activated protein kinase kinase (MEK) inhibitors at the time of LMD diagnosis.